Previous Article | Next Article ![]()
Infection and Immunity, January 2003, p. 132-139, Vol. 71, No. 1
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.1.132-139.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Institute for Animal Health, Compton Laboratory, Compton, Newbury, Berks RG20 7NN, United Kingdom,1 Institute for Veterinary Microbiology, The Royal Veterinary and Agricultural University, DK-1870 Frederiksberg C, Denmark2
Received 4 April 2002/ Returned for modification 3 August 2002/ Accepted 25 September 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Milk from the uninfected gland contains leukocytes, including macrophages, neutrophils, and lymphocytes, typically at <150,000 cells/ml. Infection usually results in an inflammatory response which leads to an increase in the number of cells, primarily due to the influx of neutrophils from the peripheral circulation (23). Milk from clinically infected quarters usually contains in excess of 2,000,000 cells/ml; >90% of these are neutrophils (22). The inflammatory reaction and the increase in the number of neutrophils result in a lower rate of milk production and a gross deterioration of the quality of the secretion.
Phagocytosis and killing of bacteria by neutrophils constitute a major defense mechanism of the lactating bovine mammary gland. This process is responsible for controlling infections caused by S. aureus (24) and eliminating infections caused by E. coli (13). The role of phagocytic cells in the control of infection by S. uberis appears less clear (10). However, it was demonstrated that a capsular strain of S. uberis (0140J) was more capable of establishing an infection in the lactating gland than a noncapsular strain (EF20), which was readily eliminated (14, 20).
Experimental infection of the mammary gland with virulent strains of S. uberis results in the appearance of large numbers of neutrophils in the interstitial tissues and secretion (10, 25). However, these do not reduce the number of S. uberis organisms present in the secretion (10). Microscopic examination of infected tissues showed that bacteria detected in the secretion were found only rarely in association with phagocytic cells, and in no instance were these identified as neutrophils (25).
The ability of S. uberis to resist the bactericidal action of neutrophils has been reproduced in vitro by growth of this organism in media containing casein-derived peptides (18) or milk whey produced following the action of rennin on skim milk (1). The ability to alter the resistance of this organism to phagocytosis in vitro, by altering growth conditions, has enabled a comparison of individual strains that exhibit phagocytosis-resistant and -susceptible phenotypes. In these experiments, the production of a hyaluronic acid capsule correlated with the ability to resist phagocytosis by neutrophils (18). Removal of the capsule and inhibition of its reformation with hyaluronidase resulted in a significant reduction in the ability of S. uberis to resist phagocytosis by neutrophils in vitro (18). Capsulation in S. uberis was shown to be dependent on the presence of at least two genes (26) by the production of mutants in which the synthesis of hyaluronic acid was blocked by lesions in either hasA (hyaluronate synthase) or hasC (UDP-glucose pyrophosphorylase). Furthermore, this study showed in vitro that the capsule is a significant barrier to the efficient uptake and killing of S. uberis by bovine neutrophils (26).
Current evidence would therefore indicate that the resistance of S. uberis to phagocytosis and killing by bovine neutrophils is mediated through a hyaluronic acid capsule. In this communication, we report the first use of a genetically altered strain of S. uberis (TRF0-6) to determine the role of the capsule in vivo in an experimental model of infection in the target species.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Analysis of S. uberis for the distribution of has-related genes in field isolates by multiplex PCR. The distribution of two of the three has genes (hasA and hasB) in S. uberis (26) was investigated by multiplex PCR, and the distribution of hasC (26) was investigated by single-gene PCR. The strain collection kept at the Cattle Health Laboratory (Broerup, Denmark) consisted of samples from 19 Danish dairy herds; 77 strains were isolated from cases of clinical mastitis in lactating cattle, and 103 strains were isolated from bedding materials. All isolates were cultivated on blood agar containing esculin and putatively identified as S. uberis following analysis by using the API-20 STREP system (bioMerieux).
Confirmation of the species-level identification was achieved by multiplex PCR for the simultaneous identification of S. uberis 23S rRNA gene sequences for hasA and hasB. The PCR included 0.8x PCR buffer (Applied Biosystems); 200 µM each dATP, dCTP, dGTP, and dTTP (Applied Biosystems); primers (0.075 to 0.3 µM each) (Table 1); 2.5 µM MgCl2; 1.25 U of Taq DNA polymerase (Applied Biosystems); genomic DNA template (5 µl); and autoclaved ultrafiltered water to a final volume of 50 µl. Oligonucleotide primer pairs were designed with Gene Fisher software (7) on the basis of DNA sequences for the genes hasA and hasB (GenBank accession no. AJ242946) and hasC (GenBank accession no. AJ400707). For the identification of S. uberis, oligonucleotide primers designed for a specific part of the 23S rRNA gene were used (9). All oligonucleotide primers were obtained from a commercial source (DNA-technology, Aarhus, Denmark). The concentrations of the primers used in the PCR as well as the expected sizes of the four different amplicons are shown in Table 1.
|
Experimental challenge with S. uberis strains 0140J and TRF0-6. Six dairy cows in their first lactation were each challenged in two mammary gland quarters by infusion of between 600 and 1,000 CFU of S. uberis suspended in 1 ml of pyrogen-free saline (Sigma). Two animals were challenged with S. uberis strain 0140J, and four animals were challenged with strain TRF0-6. Animals were challenged in two groups of three (one with 0140J and two with TRF0-6 in each group). Animals were housed in contained experimental facilities and milked twice daily at 0700 and 1600. Each animal was milked by using a separate unit to ensure no cross contamination between animals. Samples were collected at each milking for the enumeration of bacteria and somatic cells as described previously (5, 6). Animals were assessed clinically at each milking, and those in which predetermined criteria for clinical end points (clotted and discolored milk and/or swollen or painful udder quarters) had been reached were treated with proprietary branded antibiotics.
RFLP of chromosomal DNA. Bacterial colonies isolated following experimental challenge were transferred to Todd-Hewitt broth and grown at 37°C for 18 h. Chromosomal DNA was isolated (26) and subjected to restriction fragment length polymorphism (RFLP) analysis (12). The RFLP profiles were compared to those obtained following a similar analysis of cultures of the challenge strains TRF0-6 and 0140J.
PCR amplification of the hasA gene sequence in isolates recovered following challenge. Bacterial colonies isolated following enumeration of bacteria from milk samples obtained following experimental challenge were transferred to Todd-Hewitt broth and grown at 37°C for 18 h. A sample (5 µl) from each culture was heated at 100°C for 5 min and used as a source of template DNA for the amplification of hasA by PCR with the procedures and primers described previously (26). The amplification products were compared to those obtained from cultures of each of the challenge strains, 0140J and TRF0-6.
Measurement of the bactericidal action of bovine neutrophils. The bactericidal action of bovine neutrophils against various bacteria was determined. In order to compare the data obtained here with those obtained previously, strains of S. uberis were subjected to an assay similar to that used in earlier studies (18, 20, 26). Briefly, 0.5 ml of a washed bacterial suspension (106 CFU/ml) in phosphate-buffered saline (PBS) was mixed with 1.0 ml of a suspension of bovine neutrophils (107 cells/ml) and 1.5 ml of aseptically collected bovine skim milk. The mixtures were rolled at 120 rpm for 180 min on a Coulter roller (Coulter Electronics) at 37°C. Samples (100 µl) were removed, and the total number of viable bacteria was determined. The data obtained were compared to those obtained from a similarly incubated bacterial suspension to which the same volume of PBS but no neutrophils had been added.
This assay was also adapted to determine the ability of neutrophils to function in the milk in which S. uberis strains 0140J and TRF0-6 had been cultivated. Bacterial cells were removed from a milk culture (24 h, 37°C) by centrifugation (15,000 x g, 15 min), and the milk was sterilized by filtration (0.2-µm-pore-size filter). The culture filtrate (1.5 ml) was mixed with 100 µl of peripheral blood neutrophils (108 cells/ml) and 50 µl of E. coli strain P4 (108 CFU/ml). The mixtures were rolled at 120 rpm for 180 min on a Coulter roller at 37°C. Samples (100 µl) were removed, and the total number of viable bacteria was determined. The data obtained were compared to those obtained from assays in which filtered milk that had been incubated at either 37 or 4°C for 24 h in the absence of bacteria was used in place of the milk culture filtrate. Each assay was also controlled by comparison to identical assays from which neutrophils were omitted.
In all experiments, at least three independent assays were conducted in triplicate and bacterial numbers were estimated following dilution of samples in isotonic saline and incubation of 50 µl of each dilution on blood agar containing 1% (wt/vol) esculin at 37°C for 18 h.
Determination of the ability of S. uberis in milk cultures to withstand the bactericidal action of bovine neutrophils. The ability of S. uberis strains 0140J and TRF0-6 to resist the bactericidal action of neutrophils following growth in bovine milk was assessed. Bacteria were cultured in bovine skim milk at 37°C for 24 h, and 2.4 ml of this culture was mixed with 100 µl of a suspension of isolated peripheral blood neutrophils (108 cells/ml of PBS). The mixtures were rolled at 120 rpm for 180 min on a Coulter roller at 37°C. Samples (100 µl) were removed, and the total number of viable bacteria was determined. The data obtained were compared to those obtained from a similarly incubated bacterial culture to which the same volume of PBS but no neutrophils had been added. The number of bacteria was determined by dilution of samples in isotonic saline and direct plating as described above. This assay was conducted in triplicate on three separate occasions.
| RESULTS |
|---|
|
|
|---|
|
|
|
Experimental challenge with S. uberis strains 0140J and TRF0-6. The virulence of a well-characterized strain of S. uberis, 0140J, and that of its mutant derivative, TRF0-6, which lacks the ability to produce hyaluronic acid due to insertional disruption of its single copy of hasA (26), were compared in a well-established experimental model (5, 6, 10, 14, 15, 19) for bovine mastitis.
S. uberis was isolated in pure cultures from milk obtained from the first milking postchallenge in all animals. In each sample, the bacteria were shown to be of the correct strain lineage by RFLP analysis (data not shown) and genotype by PCR amplification of the appropriately sized products (950 bp for 0140J and 1,750 bp for TRF0-6) from the hasA gene (Fig. 3).
|
|
|
Inflammatory responses (Fig. 5) and bacterial recoveries (Fig. 4) measured in both groups of animals were similar and were therefore not dependent on the challenge strain.
Resistance to the bactericidal action of bovine neutrophils. The failure of animals to clear the noncapsular mutant following experimental challenge was in marked contrast to the interaction between this strain and bovine neutrophils reported previously in studies conducted in vitro (26).
In order to confirm the earlier data, both strains were grown in CDM-CH, known to induce capsule expression in the wild-type strain (18). Washed bacterial suspensions were subjected to a bactericidal assay similar to that used previously (18, 20, 26). The data obtained here were similar to those obtained before and confirmed that the noncapsular mutant was considerably less able to resist the bactericidal action of neutrophils than the capsular parental strain in such an assay (Fig. 6). These data were not consistent with the observations in vivo, where both strains appeared to survive at similar levels in the presence of neutrophils.
|
To investigate whether the additional hypothesized antiphagocytic component was cell associated and/or released into milk during bacterial growth, two further experiments were conducted. In the first experiment, strains 0140J and TRF0-6 were grown in milk, collected, and washed, and their ability to withstand the bactericidal action of bovine neutrophils was compared to that of washed suspensions of the same strains following growth in CDM-CH (Fig. 6). The two strains extracted from milk cultures survived at levels similar to each other and to the level of the noncapsular mutant grown in CDM-CH. Each of these cultures was significantly (P < 0.001) less able to resist the bactericidal action of neutrophils than the parental strain cultured in CDM-CH (Fig. 6). In the second experiment, the effect of filtrates from milk cultures of either 0140J or TRF0-6 on the bactericidal action of bovine neutrophils was determined. Bovine neutrophils were added to milk culture filtrates, and a washed suspension of E. coli (strain P4) was added to the mixture as a reporter of bactericidal action. Filtered milk that had not been used to culture bacteria but that had been incubated at either 4 or 37°C was used as a control medium. Similarly, the viability of the reporter in each medium was determined in the absence of neutrophils. Milk that had not been used to culture S. uberis supported the bactericidal action of neutrophils, and milk that did not contain neutrophils supported the growth of E. coli. However, milk in which either 0140J or TRF0-6 had been cultured was significantly (P < 0.001) less able to support the bactericidal action of neutrophils (Fig. 7).
|
| DISCUSSION |
|---|
|
|
|---|
Following challenge, infection was established in all quarters challenged with the wild-type strain and the hasA mutant. Of these, 100 and 75%, respectively, showed overt clinical signs of disease. In compliance with legislation in the United Kingdom on the use of experimental animals, each animal showing clinical signs of disease was treated with antibiotics. In no instance were bacteria eliminated from the mammary gland in the absence of antibiotic therapy, indicating that intact hasA and consequently the hyaluronic acid capsule were not required for infection. Furthermore, the influx of neutrophils into the mammary gland did not result in a decrease in the number of bacteria present in the secretion, indicating that the absence of the capsule did not noticeably alter the resistance of the bacteria to the bactericidal action of bovine neutrophils in vivo. These results are consistent with the results of previous studies on infection of the bovine mammary gland with wild-type S. uberis (5, 6, 10, 14, 15, 19) but are in contrast to results obtained with other mastitis pathogens, such as E. coli (13) and Staphylococcus aureus (24), where an influx of neutrophils corresponds to a decrease in bacterial numbers and even elimination of the infecting organisms.
This infection model has been used on a number of occasions by various researchers (5, 6, 10, 14, 15, 19) and typically yields clinical disease in approximately 90% of challenges with strain 0140J. Failure to generate clinical disease in two quarters (both on the same animal) out of eight quarters challenged with the hasA mutant may indicate a minor reduction in the virulence of this strain. However, in light of the importance of neutrophils in controlling intra-mammary gland infection, this result did not reflect the requirement for the capsule hypothesized from earlier studies conducted in vitro (1, 2, 18, 20, 26). Given the similarity of the responses of animals challenged with the mutant strain and animals challenged with the parental strain in both this study and previous studies (5, 6, 10, 14, 15, 19), it is considered unlikely that the absence of clinical mastitis in one animal was due solely to the absence of a capsule on the challenge strain. In the animal that did not show overt signs of disease, the mutant strain persisted in the presence of a potentially overwhelming neutrophil response (more than 10 neutrophils per CFU) in both quarters for 120 h (the duration of the experiment), indicating that even in this animal, the mutant strain was able to withstand the bactericidal action of incoming neutrophils.
A comparison of the abilities of two field strains (0140J and EF20) to withstand the bactericidal action of neutrophils in vitro, to produce a capsule (20), and to infect the lactating mammary gland (15) led to the conclusion that these observations were linked. Strain EF20 was considered to have reduced virulence due to the absence of a capsule and a consequent reduction in its resistance to the bactericidal action of neutrophils. In this study and in a previous investigation (26), strain TRF0-6 was also shown to be unable to resist the bactericidal action of neutrophils during bactericidal assays similar to those used previously with strain EF20. Strain TRF0-6 was also shown to be unable to produce detectable levels of hyaluronic acid due a lesion within its single copy of hasA (26). In this study, it was shown clearly that strain TRF0-6 was able to infect the bovine mammary gland (eight of eight challenges) and cause clinical mastitis (six of eight challenges). These results are in contrast to those of a previous study, carried out with the same infection model, which showed that strain EF20 was able to infect only 2 out of 18 challenged quarters; in comparison, in the same experiment, strain 0140J caused clinical disease in 16 out of 18 challenged quarters (15). Therefore, although the present investigation confirmed that the capsule is able to confer resistance to the bactericidal action of neutrophils under some assay conditions in vitro, it also leads to the conclusion that such assays do not accurately reflect all of the possible interactions between bacteria and neutrophils in vivo. These data also cast doubt on the original interpretation that strain EF20 showed reduced virulence, compared to strain 0140J, due to the absence of a capsule (15, 20) and imply that another, unidentified difference relating to virulence exists between these two field strains.
In the field, S. uberis infections of the bovine mammary gland arise predominantly as a result of challenge at the teat end from bacteria present in environmental reservoirs, such as bedding materials. If the presence of the capsule is of greater significance to the pathogenesis of disease than to environmental survival, then it is likely that the expression of the capsule will be an overrepresented phenotypic characteristic in a collection of isolates obtained from cases of mastitis. For S. uberis, it has been demonstrated that the presence of both hasA and hasC is required for capsule production (26); consequently, of the two genotypes of S. uberis detected in this study, only hasABC can be predicted to have the genetic capability for capsule production. This genotype occurred at a higher frequency in the isolates associated with disease, suggesting that the capsule is required for some aspects of intra-mammary gland infection and pathogenesis. It is considered unlikely that the minor perturbation of virulence that we observed in one out of the four animals challenged with the noncapsular mutant would account for the difference in the distribution of potentially capsular and noncapsular genotypes. With the infection model used in the present investigation, bacteria are placed beyond the teat canal, into the cistern of the mammary gland; therefore, this model does not allow investigation of all of the possible aspects of infection in the field. As a result, it can be hypothesized that during infection in the field, the capsule may play a role in teat end colonization and/or teat canal penetration.
The role of the hyaluronic acid capsule of S. pyogenes (Lancefield group A streptococci) has been investigated in vitro and in vivo, in mouse models of colonization and disease. While the majority of the studies indicated a role for the capsule, the manifestation of its effects in vitro differed according to the presence of serum, whole blood (21), or fibrinogen (3). In these situations, the consequence of the absence of the capsule was less marked due to the presence of an alternate antiphagocytic mechanism, namely, M protein. It would appear that with S. uberis, infection of the bovine mammary gland is a particular and specialized circumstance in which the hyaluronic acid capsule appears to have little relevance for resistance to the action of phagocytic cells during the pathogenesis of infection.
The present investigation led to the hypothesis that a factor or factors other than the capsule must be able to effect the resistance of S. uberis to killing by bovine neutrophils. This hypothesis was substantiated following the demonstration that neutrophils added directly to milk-grown cultures were unable to kill either the wild type or the noncapsular mutant. This observation was in agreement with those obtained in vivo, where neither strain was cleared or even reduced in number following the influx of neutrophils. This observation was not attributable to the induction of a factor associated with bacterial cells, as washed suspensions of either strain grown in this medium were unable to withstand the bactericidal action of bovine neutrophils effectively. However, cell-free filtrates from milk-grown cultures of either strain were shown to be unable to support the bactericidal action of neutrophils, suggesting that the resistance of S. uberis to neutrophil-mediated killing may be effected through an extracellular factor.
As the bacterium used as a reporter of bactericidal action, E. coli, and S. uberis are not immunologically cross-reactive and as the opsonization of either bacterial species can be effected by antibody alone (4, 11, 18, 28), it is considered unlikely that the inability of milk culture filtrates to support phagocytosis was due to the specific depletion of opsonin. Furthermore, nonspecific depletion of immunoglobulin by S. uberis is not considered likely, as S. uberis does not produce any detectable antibody binding proteins and binds antibody only in an antigen-dependent manner (18).
An extracellular factor(s) capable of inhibiting neutrophils has been reported for S. uberis 0140J (4), and other strains of S. uberis have been shown to exert an inhibitory effect against bovine macrophages (2). It is possible, therefore, that material released or secreted by either 0140J or its noncapsular mutant derivative, TRF0-6, was capable of inhibiting phagocytic killing by bovine neutrophils. A previous interpretation of these observations (2, 4), in light of data from in vitro studies supporting the role of the capsule, led to the conclusion that this effect was exerted only in concert with the capsule. However, the data presented in this communication have separated the presence of the capsule and an inhibitory effect, thus demonstrating their functional and genetic independence.
In conclusion, many of the isolates from cases of bovine mastitis possessed a hyaluronic acid capsule, implying a role for this structure. The data presented in this communication suggested that the role of the capsule with respect to the pathogenesis of bovine mastitis is limited but implied that the capsule may exert an effect at the level of penetration of the mammary gland. Furthermore, these data alluded to the possibility that following entry into the bovine mammary gland, S. uberis may be able to produce an environment in which the bactericidal effect exerted by the influx of neutrophils is inhibited. Even in the absence of a capsule, this effect appears to be sufficient to permit persistence of the infection to a level at which it results in the induction of clinical mastitis in the target species. Given previous reports (2, 4), this finding may reflect the production of an activity capable of inhibiting neutrophil function. However, the nature and precise mode of action of this inhibitory activity are yet to be established.
| ACKNOWLEDGMENTS |
|---|
The authors from the Institute for Animal Health acknowledge the financial support of the Ministry of Agriculture, Fisheries, and Food (now the Department for the Environment, Food, and Rural Affairs, United Kingdom).
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
| 1. | Almeida, R. A., and S. P. Oliver. 1993. Growth curve, capsule expression and characterization of the capsular material of selected strains of Streptococcus uberis. Zentbl. Veterinaermed. 40:697-706. |
| 2. | Almeida, R. A., and S. P. Oliver. 1993. Antiphagocytic effect of the capsule of Streptococcus uberis. Zentbl. Veterinaermed. 40:707-714. |
| 3. | Dale, J. B., R. G. Washburn, M. B. Marques, and M. R. Wessels. 1996. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64:1495-1501.[Abstract] |
| 4. | Field, T. R., P. M. Norton, A. P. Bland, and J. A. Leigh. 1997. Changes in bovine neutrophils induced by the capsule of Streptococcus uberis. Adv. Exp. Med. Biol. 418:957-960.[Medline] |
| 5. | Finch, J. M., A. W. Hill, T. R. Field, and J. A. Leigh. 1994. Local vaccination with killed Streptococcus uberis protects the bovine mammary gland from experimental infection following intramammary challenge with the same strain. Infect. Immun. 62:3599-3603. |
| 6. | Finch, J. M., A. Winter, A. Walton, and J. A. Leigh. 1997. Further studies on the efficacy of a live vaccine against mastitis caused by Streptococcus uberis. Vaccine 15:1138-1143.[CrossRef][Medline] |
| 7. | Giegerich, R., F. Meyer, and C. Sleichermacher. 1996. Gene Fishersoftware support for the detection of postulated genes, p. 68-77. ISMB-96. In D. J. States, P. Agarwal, T. Gaasterland, L. Hunter, and R. F. Smith (ed.), Proceedings of the Fourth International Conference on Intelligent Systems for Molecular Biology. AAAI Press, Menlo Park, Calif. |
| 8. | Guidry, A. J. 1985. Mastitis, p. 237-262. In B. L. Larson (ed.), Lactation. Iowa State University Press, Ames, Iowa. |
| 9. | Hassan, A. A., I. U. Khan, A. Abdulmawjood, and C. Lammler. 2001. Evaluation of PCR methods for rapid identification and differentiation of Streptococcus uberis and Streptococcus parauberis. J. Clin. Microbiol. 39:1618-1621. |
| 10. | Hill, A. W., J. M. Finch, J. A. Leigh, and T. R. Field. 1994. Immune modification of the pathogenesis of Streptococcus uberis mastitis in the dairy cow. FEMS Immunol. Med. Microbiol. 8:109-118.[CrossRef][Medline] |
| 11. | Hill, A. W., D. J. S. Heneghan, T. R. Field, and M. R. Williams. 1983. Increase in specific opsonic activity in bovine milk following experimental Escherichia coli mastitis. Res. Vet. Sci. 35:222-226.[Medline] |
| 12. | Hill, A. W., and J. A. Leigh. 1989. DNA fingerprinting of Streptococcus uberis: a useful tool for epidemiology of bovine mastitis. Epidemiol. Infect. 103:165-171[Medline] |
| 13. | Hill, A. W., A. L. Shears, and K. G. Hibbit. 1978. The elimination of serum resistant Escherichia coli from experimentally infected mammary glands of healthy dairy cows. Res. Vet. Sci. 25:89-93.[Medline] |
| 14. | Hill, A. W. 1988. Protective effect of previous intramammary infections with Streptococcus uberis against subsequent clinical mastitis in the cow. Res. Vet. Sci. 44:386-391.[Medline] |
| 15. | Hill, A. W. 1988. Pathogenicity of two strains of Streptococcus uberis infused into the lactating and non-lactating mammary gland. Res. Vet. Sci. 45:400-404.[Medline] |
| 16. | Hillerton, J. E., M. F. S. Shearn, R. M. Teverson, S.Langridge, and J. M. Booth. 1993. Effect of pre-milking teat dipping on clinical mastitis on dairy farms in England. J. Dairy Res. 60:31-41.[Medline] |
| 17. | Kossaibati, M. A., and R. J. Esslemont. 1997. The costs of production diseases in dairy herds in England. Vet. J. 154:41-51.[CrossRef][Medline] |
| 18. | Leigh, J. A., and T. R. Field. 1994. Streptococcus uberis resists phagocytosis despite the presence of bound immunoglobulin. Infect. Immun. 62:1854-1859. |
| 19. | Leigh, J. A., J. M. Finch, T. R. Field, N. C. Real, A. Winter, A. W. Walton, and S. M. Hodgkinson. 1999. Vaccination with the plasminogen activator from Streptococcus uberis induces an inhibitory response and protects against experimental infection in the dairy cow. Vaccine 17:851-857.[CrossRef][Medline] |
| 20. | Leigh, J. A., T. R. Field, and M. R. Williams. 1990. Two strains of Streptococcus uberis, of differing ability to cause clinical mastitis, differ in their ability to resist some host defence factors. Res. Vet. Sci. 49:85-87.[Medline] |
| 21. | Moses, A. E., M. R. Wessels, K. Zalcman, S. Alberti, S. Natanson-Yaron, T. Menes, and E. Hanski. 1997. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect. Immun. 65:64-71.[Abstract] |
| 22. | Paape, M. J., W. P. Wergin, A. J. Guidry, and W. D. Schultze. 1981. Phagocytic defense of the ruminant mammary gland. Adv. Exp. Med. Biol. 137:555-578.[Medline] |
| 23. | Persson, K., I. Larsson, and C. Hallen-Sandgren. 1993. Effects of certain inflammatory mediators on bovine neutrophil migration in vivo and in vitro. Vet. Immunol. Immunopathol. 37:1464-1466. |
| 24. | Schalm, O. W., J. Lasmanis, and N. C. Jain. 1976. Conversion of chronic staphylococcal mastitis to acute gangrenous mastitis after neutropenia in blood and bone marrow produced by an equine anti-bovine leucocyte. Am. J. Vet. Res. 37:885-890.[Medline] |
| 25. | Thomas, L. H., W. Haider, A. W. Hill, and R. S. Cook. 1994. Pathologic findings of experimentally induced Streptococcus uberis infection in the mammary gland of cows. Am. J. Vet. Res. 55:1723-1728.[Medline] |
| 26. | Ward, P. N., T. R. Field, W. G. F. Ditcham, E. Maguin, and J. A. Leigh. 2001. Identification and disruption of two discrete loci encoding hyaluronic acid capsule biosynthesis genes hasA, hasB, and hasC in Streptococcus uberis. Infect. Immun. 69:392-399. |
| 27. | Watts, J. L. 1988. Etiologic agents of bovine mastitis. Vet. Microbiol. 16:41-66.[CrossRef][Medline] |
| 28. | Williams, M. R., and A. W. Hill. 1982. A role for IgM in the in vitro opsonisation of Staphylococcus aureus and Escherichia coli by bovine polymorphonuclear leukocytes. Res. Vet. Sci. 33:47-53.[Medline] |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|